基于改良静脉过量超声引导的液体平衡与标准护理在急性肾损伤患者接受连续性肾脏替代治疗中的比较 (mVExUS-CRRT)
改良静脉超负荷超声引导液体平衡对比标准治疗在急性肾损伤患者连续肾脏替代治疗中的应用:一项多中心随机对照试验
The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.
The main questions it aims to answer are:
Does fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care
Participants will:
Get fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours
研究概览
地位
详细说明
After enrollment, the participants have to be randomized within 1 h. In the intervention arm, mVExUS has to be performed every 24 hours until 72 hours after enrollment. Participants with profile A will have UFNET 0 mL/hr with target fluid balance 0 to +500 mL/day. Patients with profile B will have UFNET 0-20 mL/hr with target fluid balance 0 to -500 mL/day. Patients with profile C will have UFNET 20-40 mL/hr with target fluid balance -500 to -1000 mL/day. Patients with profile D will have UFNET 40-100 mL/hr with target fluid balance neg >1000 mL/day.
This intervention will be combined with serial lactate monitoring in which lactate levels will be measured every 8 h. When the lactate level rises more than 2 or if there is presence of HIRRT (tachycardia, hypotension, mottling or drop in cardiac index), passing leg raising or mini-fluid challenge (crystalloid fluid bolus 200 mL) will be performed to assess fluid responsiveness. If there is fluid responsiveness, UFNET will be stopped. Once lactate is normalized or episode of HIRRT resolved, the UFNET strategy has to be restored.
The CRRT technique (haemodialysis, haemofiltration, haemodiafiltration) will be left at the discretion of the treating team. CRRT dose (i.e. dialysate or reinfusion fluids flow rate) will be prescribed at 25-30 ml/kg/hr according to the KDIGO guideline. CRRT dose and UFNET will be indexed to the patient's body weight, and in patients with a body mass index at 30 kg/m2, to the adjusted body weight (calculated as ideal body weight to which will be added 40% of the difference between the actual body weight and the ideal body weight - Du Bois formula). Choice of extra-corporeal circuit anticoagulation (heparin, citrate or none) and implantation site of CRRT catheters will be left at the discretion of the treating physician.
Vasopressors will be titrated as per unit-based protocols to maintain the mean arterial pressure within the bounds prescribed by the physician in charge (most frequently between 65 and 75 mmHg). Indications and category of vasopressors and inotropes will be left at the discretion of the treating team. The diuretic will be stopped once the patient is enrolled.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:thanphisit trakarnvanich, Bachelor's Degree
- 电话号码:+66896996830
- 邮箱:thanphisit2@hotmail.com
学习地点
-
-
-
Bangkok、泰国、10330
- 招聘中
- King Chulalongkorn Memorial Hospital
-
接触:
- Nuttha Lumlertgul, PhD
- 电话号码:+66896996830
- 邮箱:nlumlertgul@gmail.com
-
Bangkok、泰国、10300
- 尚未招聘
- Vajira Hospital, Navamindradhiraj University
-
接触:
- Thanphisit Trakarnvanich
- 电话号码:+66896996830
- 邮箱:thanphisit2@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults (≥ 18 years of age)
- Admitted to ICU
- Acute kidney injury by KDIGO criteria
- Initiated CRRT by at least one of the following indications for RRT initiation:
- Serum potassium ≥ 6.0 mmol/L, or
- pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L, or
- Evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload, or
- Persistent severe AKI (sCr remains > 50% the value recorded at randomization) for > 72 hours from randomization
- Participants giving informed consent
Exclusion Criteria:
- Refuse to participate
- Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy
- Kidney transplant recipient
- Receive RRT before ICU admission within 90 days
- Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease
- Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites.
- Underlying disease process with a life expectancy less than 90 days
- Pregnancy
- Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia)
- Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect
- Aortic aneurysm
- Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg)
- Expected life expectancy <48 hours
- Receiving extracorporeal membrane oxygenation (ECMO)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:标准护理
|
|
|
有源比较器:mVExUS引导的液体管理
|
In the intervention arm, mVExUS has to be performed every 24 hours until 72 hours after enrollment. Participants with profile A will have UFNET 0 mL/hr with target fluid balance 0 to +500 mL/day. Patients with profile B will have UFNET 0-20 mL/hr with target fluid balance 0 to -500 mL/day. Patients with profile C will have UFNET 20-40 mL/hr with target fluid balance -500 to -1000 mL/day. Patients with profile D will have UFNET 40-100 mL/hr with target fluid balance neg >1000 mL/day. This intervention will be combined with serial lactate monitoring in which lactate levels will be measured every 8 h. When the lactate level rises more than 2 or if there is presence of HIRRT (tachycardia, hypotension, mottling or drop in cardiac index), passing leg raising or mini-fluid challenge (crystalloid fluid bolus 200 mL) will be performed to assess fluid responsiveness. If there is fluid responsiveness, UFNET will be stopped. Once lactate is normalized or episode of HIRRT resolved, the UFNET strat |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
72-hour cumulative fluid balance between mVExUS-guided management and standard care in critically ill patients with acute kidney injury receiving CRKT.
大体时间:Hour 0, Hour 72
|
In the mVExUS-guided management the fluid removal rate will be guided based on mVExUS ultrasound results. In standard care the fluid removal rate is based on conventionval fluid assessment |
Hour 0, Hour 72
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
mVExUS引导的液体管理与标准护理相比的28天和90天死亡率
大体时间:28 天,90 天
|
28 天,90 天
|
|
AKI亚型(按血管生成素-1、血管生成素-2和可溶性TNF受体-1分类)与接受CRRT治疗的危重症急性肾损伤患者死亡风险的关联
大体时间:28天
|
28天
|
|
在采用mVExUS引导的液体管理患者与接受标准护理的患者之间,CRRT相关并发症(包括透析中低血压和心律失常)的比例
大体时间:第0小时, 第72小时
|
第0小时, 第72小时
|
|
急性肾损伤危重症患者接受CRRT治疗中液体积累与净超滤轨迹的差异模式及其与28天死亡率差异的相关性
大体时间:28天
|
28天
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 0449/2568
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The datasets used and/or analysed will be available from the corresponding author on reasonable request.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.